Twist Bioscience Corporation $TWST Shares Bought by Bayforest Capital Ltd

Bayforest Capital Ltd grew its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 33.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,480 shares of the company’s stock after purchasing an additional 1,620 shares during the quarter. Bayforest Capital Ltd’s holdings in Twist Bioscience were worth $238,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. ARK Investment Management LLC grew its position in shares of Twist Bioscience by 11.5% during the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company’s stock worth $245,045,000 after acquiring an additional 645,730 shares during the last quarter. Vanguard Group Inc. grew its position in Twist Bioscience by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company’s stock valued at $230,356,000 after buying an additional 60,276 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock valued at $95,883,000 after acquiring an additional 1,588,587 shares during the period. EdgePoint Investment Group Inc. acquired a new stake in Twist Bioscience in the first quarter valued at $43,705,000. Finally, Goldman Sachs Group Inc. lifted its holdings in Twist Bioscience by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after acquiring an additional 37,577 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Evercore ISI dropped their price objective on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, October 8th. Finally, Barclays decreased their target price on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a report on Thursday, October 2nd. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $48.56.

Twist Bioscience Stock Performance

Shares of TWST opened at $30.75 on Friday. The business’s 50 day moving average is $27.93 and its two-hundred day moving average is $32.38. Twist Bioscience Corporation has a 52-week low of $24.07 and a 52-week high of $55.33. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -21.21 and a beta of 2.38. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The company had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 31,348 shares of the company’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $32.19, for a total transaction of $1,009,092.12. Following the sale, the chief executive officer directly owned 601,212 shares of the company’s stock, valued at approximately $19,353,014.28. This represents a 4.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Dennis Cho sold 3,876 shares of the company’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $32.19, for a total transaction of $124,768.44. Following the transaction, the insider owned 98,710 shares of the company’s stock, valued at $3,177,474.90. This represents a 3.78% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 64,368 shares of company stock worth $2,036,204. 3.01% of the stock is owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.